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ABSTRACT
Diabetic retinopathy (DR) is a microvascular complication that typically occurs with 
greater frequency as disease duration increases. Both the American Diabetes Association 
and the International Society for Pediatric and Adolescent Diabetes make recommendations 
that patients be screened for retinopathy starting at age 10 and after a disease duration of 
greater than 2 years. Because it is important to catch DR early to prevent vision loss to the 
patient, sensitive screening techniques such as digital fundus photography are in important 
tool in this effort. The public health cost of DR complications can be effectively reduced 
by instituting smarter screening recommendations, not screening those who are at very low 
risk, and preventing vision loss by early identification and treatment of DR.
In this study, patients attending a large pediatric diabetes clinic that met the screening 
recommendations were offered DR screening using digital fundus photography. A total of 
440 patients both met screening criteria and had retinopathy screening data. Of the 440, 
203 were screened in-clinic by an opthalmologist, and 236 had already been screened by an 
outside practitioner. 5.4% of those screened in-clinic were positive for DR, while 0.42%of those 
screened elsewhere were found to be DR+. Those with retinopathy had significantly longer 
disease duration, were older at the time of screening, had higher HbA1c, and higher 
triglycerides. All of the cases had measures exceeding the screening guidelines, with a 
minimum age at screening of 13.4 years, and a minimum diabetes duration of 6.5 years.
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    It is unknown if the difference in prevalence between the two screening locations is due to a 
true difference in prevalence, or a systematic underreporting of DR in the outside-screened
group, or a combination of these factors. The screening method of the 236 screened outside
was not reported, and cases may have been missed in this cohort. Further study will need to
be done to better quantify who would benefit most from screening, but building a risk model
will require a much larger, comprehensive study. While it appears that the current screening
guidelines may be revised without decreasing sensitivity, when screening is done it must be
done using the most accurate methods in order to be most effective in catching DR in early
stages when treatment is still effective.
This study emphasizes the public health benefit to screening for diabetic retinopathy
as a routine element of diabetes management. In fact, the patients who took advantage
of screening offered by the clinic showed over 10 times the prevalence of those who had
already received screening by an outside practice, and most of these patients would have not
otherwise completed screening, even though they were within the guidelines. The benefit to
state-of-the-art digital fundus photography DR screening in this at-risk cohort is clear.
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Diabetes Mellitus is a group of disorders that involve glucose intolerance and is often associ-
ated with severe complications [1]. Specifically, patients with poorly-controlled diabetes are
at a higher risk for heart disease, stroke, as well as blindness and kidney failure related to
microvascular complications.
Type 1 diabetes is characterized by the body’s destruction of insulin-producing beta
cells by the immune system, and is most often diagnosed in adolescence. Type 2 diabetes
is characterized by insulin resistance and is generally diagnosed in adulthood [2]. Recently,
diabetes types have been characterized that include both autoimmune destruction of beta
cells and insulin resistance [3]. In either case, risk of complications increases if glucose is not
properly controlled.
In 2014, the CDC estimated that in the United States 29.1 million, or 9.3 percent of
the population had diabetes mellitus, 27.8 percent of who were undiagnosed [1]. Diabetes
specifically in youth is more difficult to characterize, with an estimated prevalence of 0.18
percent in 2006, with greater than 80 percent of these cases being Type 1 diabetes [4],
compared to approximately 5 percent in adults [1].
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1.2 DIABETIC RETINOPATHY
Diabetic retinopathy (DR) is a microvascular complication that is related to nephropathy and
neuropathy. Specifically, damage to the retina tissue causes retinal blood vessles to weaken
and form microanurysms and possibly hemmorhage. Patients are often asymptomatic until
the disease has progressed far enough along that treatment is no longer effective [5]. Left
untreated, DR can become proliferative and lead to a loss of vision. Therefore, it is imperative
to identify the presence of DR early in its progression so that treatment can remain effective.
1.2.1 Disease Stages
The progression of DR can be classified into one of four stages, depending on swelling,
blockage of retinal blood vessels, and presence of proliferation:
• Non-proliferative retinopathy: characterized by tiny microaneurysms that may leak fluid.
The non-proliferative stage is further sub-staged into mild, moderate, and severe non-
proliferative retinopathy
• Proliferative diabetic retinopathy: new blood vessels are growing into the retina, leaking
and obscuring vision
1.2.2 Risk Factors
In children and adolescents, retinopathy most commonly occurs after puberty onset and after
at least 5 years of diabetes duration[6]. Duration of disease is a known major risk factor, as
is poor glycemic control and high blood pressure.
In adults, retinopathy is 4 times more common in Type 1 patients than Type 2 patients
[7]. This is understandable, because Type 1 patients are more likely to have been diagnosed
at a young age, and therefore to have experienced a longer disease duration. This relation-
ship may not translate well to a pediatric population, however, because of the much lower
prevalence of Type 2 diabetes in this group.
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1.2.3 Screening Guidelines
In their most recent 2016 screening guidelines, the American Diabetes Association recom-
mends that screening be performed ”at age ≥ 10 or after puberty has started, whichever is




Electronic medical records from Children’s Hospital of Pittsburgh (CHP) Diabetes Center
were reviewed of patients who had been diagnosed with diabetes mellitus and had attended
the clinic in the period between February 1 and November 23, 2015. Inclusion was limited to
those patients who met the current screening guidelines for DR: age ≥ 10, diabetes duration
≥ 2. Of these patients, a classification was made as to DR screening location:
1. Screened in-clinic by CHP opthalmology
2. Screened at an outside facility or in private practice
3. No record of screening during inclusion period
Patients that were screened by CHP had an assessment of diabetic retinopathy presence
made using digital fundus photography and by two different highly trained screeners. The
assessment of Reviewer 1 was agreed upon beforehand to be the measure used in the analysis.
The screening methods of those screened at an outside facility were unreported or unknown,
although it is likely that the majority were screened using opthalomoscopy.
For this analysis, only patients in groups 1 or 2 (received screening) were considered.
Those in group 3 were either not offered screening due to logistical issues, or declined screen-




A total of 68 measures were extracted from the records. Eighteen variables were used for
this analysis, including screening result, screening location, sex, race, diabetes type, age at
screening, age at DM diagnosis, DM duration, insulin dose, BMI, systolic and diastolic blood
pressures, Hemoglobin A1c, triglycerides, and total, LDL and HDL cholesterols. For some
measures, multiple time points were available.
Urine and antibody measures were available for some patients, but were not uniformly
reported, and omitted from this analysis.
2.3 DESCRIPTIVE STATISTICS
The prevalence of DR in this population will be estimated, along with a 95% confidence
interval.
The distributions for each of the variables were characterized by both screening status
and screening location, and appropriate descriptive statistics were calculated. For measures
that were non-normal, a Wilcoxon Rank-Sum test was performed, otherwise a two-sample
t-test was performed.
2.4 REPRODUCIBILITY OF SCREENING MEASURE
The discordance of the two screening measures will be calculated using the κ-statistic, and
its reproducibility will be assessed.
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3.0 RESULTS
Four hundred and forty patients met the inclusion criteria for the analysis, 12 of who were
positive for diabetic retinopathy. Sex of the eligible patients, categorized by DR status, is
presented in Table 1. Sex was found to be a statistically significant predictor of DR screening
result, with a two-sided Fisher’s Exact p-value of 0.0018.
Diabetes type of the eligible patients is presented in Table 2. With a two-sided Fisher’s
Exact p-value of 0.1163, diabetes type was found to be statistically unrelated with DR
screening result.
Screening results by insulin delivery method are presented in Table 3. With a two-sided
Fisher’s Exact p-value of 1.000, insulin delivery method was found to be not significantly
related with DR screening result.
Races of the eligible patients is presented in Table 4. Race was found to be statistically
unrelated with DR status, with a Fisher’s Exact two-sided p-value of 0.4774.
Table 1: DR Screening Results by Sex
DR Status
Sex + - Total Prevalence 95% CI
Male 8 110 118 6.76% (2.97%, 12.92%)
Female 3 82 85 3.53% (0.73%, 9.97%)
Total 11 192 203 2.72% (1.42%, 4.72%)
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Table 2: DR Screening Results by Diabetes Type
DR Status
Diabetes Type + - Total Prevalence 95% CI
1 9 181 190 4.74% (2.19%, 8.80%)
2 2 11 13 15.38% (1.92%, 45.45%)
Total 11 192 203 2.72% (1.42%, 4.72%)
CI is 95% Exact Binomial Confidence Interval
Table 3: DR Screening Results by Insulin Delivery Method
DR Status
Delivery Method + - Total Prevalence 95% CI
Multiple Daily Injections 8 127 135 5.93% (2.59%, 11.34%)
Continuous Delivery 3 59 62 4.84% (1.01%, 13.50%)
No Insulin 0 5 5 0.00%
CI is 95% Exact Binomial Confidence Interval
Table 4: DR Screening Results by Race
DR Status
Race + - Total Prevalence 95% CI
White 9 156 165 5.45% (2.52%,10.10%)
Black 2 31 33 6.06% (0.74%,20.23%)
Other / Mixed Race 0 5 4 0.0%
Total 11 192 203 5.42% (2.74%, 9.49%)
CI is 95% Exact Binomial Confidence Interval
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Table 5: Retinopathy Screening Results by Location
DR Status
Screening Location + - Total Prevalence 95% CI
In-Clinic 192 11 203 5.42% (1.42%, 4.72%)
Outside 236 1 237 0.42% (0.01%, 2.33%)
Total 428 12 440 2.73% (1.42%, 4.72%)
CI is 95% Exact Binomial Confidence Interval
3.1 RETINOPATHY PREVALENCE
The prevalence of diabetic retinopathy in the total population studied was estimated at
2.73%, with a 95% exact binomial confidence interval of (1.21%, 4.25%).
3.2 SCREENING LOCATION
Distribution of screening location for eligible patients is shown in Table 5. 237 (53.9%)
out of 440 patients chose to be screened outside of the clinic. Retinopathy was not evenly
distributed by screening location, with all but one case occurring in the in-clinic screened
population (Fisher’s Exact p = 0.0018). Patients screened at CHP had an estimated DR
prevalence of 5.42%, while patients screened outside CHP had an estimated prevalence of
0.42%.
3.3 OVERALL CHARACTERISTICS
A summary of the overall variable characteristics is provided in Table 6.
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Table 6: Overall Characteristics
Variable Q1 Median Q3 Mean Std. Dev.
Age at Screening (years) 13.14 15.34 17.46 15.40 3.02
Age at Diagnosis (years) 5.72 8.41 10.97 8.31 3.85
DM Duration (years) 4.07 6.43 9.39 7.09 3.73
Insulin Dose (units/kg/day) 0.76 0.92 1.09 0.92 0.30
BMI (kg/m2) 20.04 22.78 25.75 23.68 5.52
BMI percentile 55.42 79.64 89.91 70.80 24.34
Systolic Blood Pressure Percentile 40.21 61.18 76.65 58.34 22.98
Diastolic Blood Pressure Percentile 60.79 72.65 81.87 69.80 16.85
HbA1c (%) 7.4 8.0 9.1 8.47 1.74
Triglycerides (mg/dl) 60 88 139 119.99 128.34
Total Cholesterol (mg/dl) 143 164 189 167.16 34.75
HDL Cholesterol (mg/dl) 46 56 66 57.05 14.82
LDL Cholesterol (mg/dl) 76 92 109 94.34 28.10
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3.4 CHARACTERISTICS BY DIABETIC RETINOPATHY SCREENING
RESULT
A summary of the variable characteristics by screening result is provided in Table 7. Median
age at screening was significantly higher in the retinopathy group, with a Wilcoxon Rank-
sum two-sided p-value of 0.003. Diabetes duration was significantly longer in the retinopathy
group, with a Wilcoxon Rank-sum two sided p-value of 0.002. HbA1c and Triglycerides were
both significantly higher in the DR group at the α = 0.05 level.
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Table 7: Subject Characteristics by DR Screening Result
Retinopathy No Retinopathy
Variable Q1 Median Q3 Q1 Median Q3 p-value
Age at Screening (years) 16.03 17.84 20.79 12.88 15.07 17.30 0.003
Age at Diagnosis (years) 6.14 7.13 12.05 6.16 9.01 11.42 0.687
DM Duration (years) 7.90 9.01 12.10 3.45 5.57 8.98 0.002
Insulin Dose (units/kg/day) 0.62 0.94 1.46 0.74 0.94 1.16 0.840
BMI (kg/m2) 20.24 23.18 28.87 19.74 22.24 25.60 0.328
BMI percentile 28.43 56.60 83.23 52.56 78.16 89.75 0.131
Systolic Blood Pressure Percentile 31.47 63.80 80.65 41.52 59.95 74.18 0.977
Diastolic Blood Pressure Percentile 61.02 78.87 87.23 62.99 72.42 81.93 0.451
HbA1c (%) 7.8 12.5 14.0 7.5 8.3 9.7 0.003
Triglycerides (mg/dl) 108 130 156 62 87 146 0.018
Total Cholesterol (mg/dl) 174 196 220 144 165 192 0.073
HDL Cholesterol (mg/dl) 53 67 72 48 57 67 0.342
LDL Cholesterol (mg/dl) 88 108 129 78 94 115 0.114
P-values based on two-sample Wilcoxon rank-sum test for equality of medians.
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3.5 CHARACTERISTICS BY SCREENING LOCATION
A summary of the variable characteristics by screening location is provided in Table 8. Age
at DM diagnosis, DM duration, Hemoglobin A1c, Total cholesterol, and LDL cholesterol
differed significantly by screening location.
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Table 8: Characteristics by Screening Location
CHP Outside
Variable Q1 Median Q3 Q1 Median Q3 p-value
Age at Screening (years) 12.94 15.36 17.45 13.42 15.29 17.46 0.632
Age at Diagnosis (years) 6.16 8.99 11.42 5.25 8.14 10.66 0.048
DM Duration (years) 3.52 5.72 9.03 4.39 6.76 9.57 0.030
Insulin Dose (units/kg/day) 0.73 0.94 1.18 0.77 0.91 1.04 0.321
BMI (kg/m2) 19.79 22.26 25.60 20.33 22.98 25.83 0.194
BMI percentile 51.91 77.19 89.95 59.01 80.12 90.61 0.276
Systolic Blood Pressure Percentile 40.21 60.06 75.31 39.74 61.42 79.11 0.733
Diastolic Blood Pressure Percentile 62.97 72.59 81.99 59.39 72.73 81.81 0.657
HbA1c (%) 7.6 8.3 9.8 7.2 7.9 8.7 0.000
Triglycerides (mg/dl) 64 89 146 58 87 131 0.326
Total Cholesterol (mg/dl) 144 166 192 143 162 181 0.035
HDL Cholesterol (mg/dl) 48 57 67 45 55 64 0.091
LDL Cholesterol (mg/dl) 79 95 116 73 89 107 0.037
P-values based on two-sample Wilcoxon rank-sum test for equality of medians.
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3.6 REPRODUCIBILITY OF SCREENING ASSESSMENT
One hundred fifty eight patients screened in-clinic had their retinal images re-analyzed by
a second reviewer. The results are displayed in Table 9. 151 of the results were agreed
upon by the reviewers, while 7 were discordant. Although the proportion of concordance
is 0.955, Cohen’s κ-statistic was calculated to be 0.5128, indicating fair-to-good agreement
between the reviewers. Additionally, Reviewer 1 identified twice as many cases than Reviewer
2. Consequently, the prevalence rate for the population is twice as high when basing the
estimate on Reviewer 1’s assessment.
Table 9: Concordance of Reviewers
Reviewer 1
+ - Total
Reviewer 2 + 4 1 5
- 6 147 153
Total 10 148 158
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4.0 DISCUSSION
The results found in this study replicate the risk factors for diabetic retinopathy found in
previous studies for both adults and adolescents. Namely, age at screening, diabetes duration,
higher HbA1c, higher blood pressure, and higher triglycerides and cholesterol were all found
to be significantly related to the development of retinopathy.
The difference in prevalence of retinopathy between the screening location groups may
either be due to a true decreased prevalence or an underreporting of the complication in the
group screened outside CHP. The variability of the measure was clearly demonstrated by
the re-reading of the images screened by CHP, and so the reliability of the screening reports
from outside sources is possibly in question. Specifically, the outside screeners did not follow
a standardized protocol and may not have used the most up-to-date screening measures,
namely opthalmoscopy instead of digital fundus photography. However, the difference in
sample characteristics may counteract the possible underreporting of retinopathy in this
group.
4.1 IMPROVEMENTS OVER PREVIOUS STUDIES
The class of patients in this analysis that did receive screening at CHP underwent a stan-
dardized protocol using the most sensitive screening method available. The difference in
prevalence between the two screening locations may indicate that this protocol is better in
identifying those positive for retinopathy, but this is uncertain because the true prevalence
of the complication is not known for the population.
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4.2 LIMITATIONS
Because patients had the option to decline screening if they had been screened somewhere
else, the sample analyzed here is not a truly random sample from the population. Patients
screened elsewhere had significantly lower risk factors for DR in HbA1c and total cholesterol,
but also had a significantly higher diabetes duration. There are likely other confounding
factors that contributed to the determination of screening location. A propensity score
analysis may be warranted to balance the effect of the choice of screening location.
Another limitation of this analysis is that the retinopathy outcome measure is binary and
the information of the stage of disease of the patient has been collapsed. This information
could be used to do an ordinal logistic regression analysis and may assist in the formulation
of a risk model.
Finally, the class of patients that did not receive screening at all may have different risk
characteristics than the other two groups. This poses a problem if those most at risk are not
receiving the necessary screening.
4.3 FUTURE DIRECTIONS
A larger study should be implemented to better assess the variables that are associated with
diabetic retinopathy in this population, with an ultimate goal in producing a risk model that
can better inform the screening guidelines.
Future work should implement a very careful and thorough screening protocol where all
subjects are screened in-house using digital fundus photography. Effort should be made to
obtain participation from all eligible subjects and reduce the numbers of patients screened
elsewhere or not at all. A possible next-step would be to re-screen all those screened elsewhere
at CHP using the standardized protocol, in order to get an estimate of under reporting of









* Calculate duration, age at onset and age at screening;
Duration = (ExamDate - DxDate)/365.25;
Age_at_dx = (DxDate - DOB)/365.25;
Age_at_screen = (ExamDate - DOB)/365.25;
* calculate if any drug;
IF (metformin OR levothyroxine OR statin OR antihypertensive OR other_meds)
THEN anyDrug = 1;
ELSE anyDrug = 0;
* Divide age groups into 5yr increments;
* recode missing;
17
total_insulin_dose = insulin_dose / weight__kg_;
IF (height__cm_=-999) THEN height__cm_=.;
IF (systolic_1=-999) THEN systolic_1=.;
IF (diastolic_1=-999) THEN diastolic_1=.;
IF (systolic_2=-999) THEN systolic_2=.;
IF (diastolic_2=-999) THEN diastolic_2=.;
IF (systolic_3=-999) THEN systolic_3=.;
IF (diastolic_3=-999) THEN diastolic_3=.;
IF (day_of_screening_hba1c__poc_=-999) THEN day_of_screening_hba1c__poc_=.;
IF (last_hba1c__poc_simultaneous_wit=-999)
THEN last_hba1c__poc_simultaneous_wit=.;
IF (Triglycerides=-999) THEN Triglycerides=.;
IF (total_Cholesterol=-999) THEN total_Cholesterol=.;
IF (c_peptide_at_diagnosis=-999) THEN c_peptide_at_diagnosis=.;
IF (Insulin_Dose=-999) THEN Insulin_Dose=.;
IF (BMI=-999) THEN BMI=.;
IF (BMI_percentile=-999) THEN BMI_percentile=.;
IF (HDL=-999) THEN HDL=.;
IF (LDL=-999) THEN LDL=.;
* Take mean of blood pressure readings;
mean_bps = MEAN(systolic_1, systolic_2, systolic_3);




FORMAT sex sexfmt. DiabetesType typefmt. retinExam screenfmt.;




IF (diabetesType IN (1,2)) and
age_at_screen >= 10 and
duration >= 2





TITLE ’Subjects not eligible’;
TITLE2 ’Age < 10, Duration < 2, Diabetes type not 1 or 2,
or Missing screening result’;
VAR MRN DOB ExamDate retinExam diabetesType age_at_screen duration;
RUN;

















TITLE2 ’by Sex / Diabetes Type’;
CLASS sex diabetesType retinExam;




TITLE2 ’by Screening Location’;
CLASS screening_location retinExam;









TITLE2 ’by Screening Result’;
TABLES gender*retinExam / fisher;
RUN;
PROC FREQ data=ret_all;
TITLE2 ’by Screening Location’;





TITLE2 ’by Screening Result’;




TITLE2 ’by Screening Location’;
TABLES race*screening_location / fisher;
RUN;
********************************** Diabetes Type ******************************;
TITLE ’Diabetes Type’;
PROC FREQ data=ret_chponly;
TITLE2 ’by Screening Result’;
TABLES DiabetesType*retinExam / fisher;
RUN;
PROC FREQ data=ret_all;
TITLE2 ’by Screening Location’;
TABLES DiabetesType*screening_location / fisher;
RUN;
***************************** Continuous Variables ****************************;
PROC UNIVARIATE data=ret_all NORMAL;
VAR age_at_screen age_at_dx duration total_insulin_dose BMI BMI_percentile
mean_bps p_sbp_score mean_bpd p_dbp_score day_of_screening_hba1c__poc_
Triglycerides Total_Cholesterol HDL LDL;
RUN;
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PROC MEANS data=ret_all MAXDEC=2 NMISS MIN Q1 MEDIAN Q3 MAX QRANGE MEAN STD CLM;
TITLE2 ’Overall’;
VAR age_at_screen age_at_dx duration total_insulin_dose BMI BMI_percentile
mean_bps p_sbp_score mean_bpd p_dbp_score day_of_screening_hba1c__poc_
Triglycerides Total_Cholesterol HDL LDL;
RUN;
PROC MEANS data=ret_chponly MAXDEC=2 NMISS
MIN P10 Q1 MEDIAN Q3 MAX QRANGE MEAN STD CLM;
TITLE2 ’by Screening Result’;
CLASS RetinExam;
VAR age_at_screen age_at_dx duration total_insulin_dose BMI BMI_percentile
mean_bps p_sbp_score mean_bpd p_dbp_score day_of_screening_hba1c__poc_
Triglycerides Total_Cholesterol HDL LDL;
RUN;
PROC npar1way data=ret_chponly anova wilcoxon plots=anovaboxplot;
TITLE2 ’Nonparametric test to compare diagnostic groups’;
CLASS retinExam;
VAR age_at_screen age_at_dx duration total_insulin_dose BMI BMI_percentile
mean_bps p_sbp_score mean_bpd p_dbp_score day_of_screening_hba1c__poc_
Triglycerides Total_Cholesterol HDL LDL;
RUN;
PROC MEANS data=ret_all MAXDEC=2 NMISS
MIN P10 Q1 MEDIAN Q3 MAX QRANGE MEAN STD CLM;
TITLE2 ’by Screening Location’;
CLASS screening_location;
VAR age_at_screen age_at_dx duration total_insulin_dose BMI BMI_percentile
mean_bps p_sbp_score mean_bpd p_dbp_score day_of_screening_hba1c__poc_
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Triglycerides Total_Cholesterol HDL LDL;
RUN;
PROC npar1way data=ret_all wilcoxon plots=wilcoxonboxplot;
TITLE2 ’Nonparametric test to compare between screening locations’;
CLASS screening_location;
VAR age_at_screen age_at_dx duration total_insulin_dose BMI BMI_percentile
mean_bps p_sbp_score mean_bpd p_dbp_score day_of_screening_hba1c__poc_
Triglycerides Total_Cholesterol HDL LDL;
RUN;
*************************** Retinopathy Prevalence ****************************;
TITLE ’Retinopathy Prevalence’;
PROC FREQ data=ret_all;
TABLES retinExam / binomial(level=2);
RUN;
TITLE ’CHP Retinopathy Prevalence’;
PROC FREQ data=ret_chponly;






TITLE ’Outside Retinopathy Prevalence’;
PROC FREQ data=ret_out;
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TABLES retinExam / binomial(level=2);
RUN;
***************************** Kappa concordance *******************************;
TITLE ’Screening Result Concordance’;
DATA retk;
SET ret_all;




TABLES retinopathy_exam_samanth*retinopathy_exam_nischal / KAPPA;
RUN;
PROC LOGISTIC data=ret_all;
CLASS race diabetestype sex;
MODEL screening_location = race diabetestype sex day_of_screening_hba1c__poc_
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